{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:31:26Z","timestamp":1781008286437,"version":"3.54.1"},"reference-count":35,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Grant-in-Aid for Encouragement of Scientists","award":["24H02620"],"award-info":[{"award-number":["24H02620"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Although therapeutic drug monitoring (TDM) maintains serum teicoplanin (TEIC) concentration between 15 and 30 \u03bcg\/mL, TEIC-induced liver injury may still occur. The albumin-bilirubin (ALBI)-fibrosis-4 (FIB-4) score may be useful for predicting TEIC-induced liver injury in patients undergoing TDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This pilot study aimed to investigate whether the ALBI-FIB4 score can predict TEIC-induced abnormal liver enzyme levels in patients undergoing TDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The multicenter retrospective cohort study included 140 patients undergoing TDM of TEIC at steady state. The primary outcome was TEIC-induced abnormal liver enzyme levels. Cut-off values for the alanine aminotransferase (ALT), ALBI score, FIB-4 index, and ALBI-FIB4 score were detected using receiver-operating characteristic curves. The cumulative risk of TEIC-induced abnormal liver enzyme levels was evaluated using Kaplan-Meier curves analyzed log-rank test. Subgroup analysis was performed to examine cumulative risk in patients with serum TEIC concentration of &lt;30 \u03bcg\/mL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The incidence of TEIC-induced abnormal liver enzyme levels was 14.3% (20\/140). Cut-off values were 24 IU\/L for ALT (sensitivity: 0.800; specificity: 0.692; area under the curve [AUC]: 0.753), \u22121.33 for the ALBI score (sensitivity: 0.550; specificity: 0.617; AUC: 0.539), 2.73 for the FIB-4 index (sensitivity: 0.700; specificity: 0.475; AUC: 0.550), and \u22120.85 for the ALBI-FIB4 score (sensitivity: 0.800; specificity: 0.467; AUC: 0.572). The cumulative risk of TEIC-induced abnormal liver enzyme levels was significantly higher for patients with ALT \u226524 IU\/L (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.01) and ALBI-FIB4 score \u2265\u22120.85 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.042). Patients with a serum TEIC concentration of &lt;30 \u00b5g\/mL exhibited a similar trend, with a higher cumulative risk for patients with ALBI-FIB4 score \u2265\u22120.85 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.058).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance:<\/jats:title>\n                    <jats:p>An ALBI-FIB4 score \u2265\u22120.85 may serve as a potential predictor for TEIC-induced abnormal liver enzyme levels in patients undergoing TDM. However, evidence supporting this threshold requires further statistical validation using a larger dataset.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251319519","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:26:43Z","timestamp":1741768003000},"page":"978-988","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The Albumin-Bilirubin\u2013Fibrosis-4 Score for Predicting Teicoplanin-Induced Abnormal Liver Enzyme Levels in Patients Undergoing Therapeutic Drug Monitoring: A Multicentral Retrospective Cohort Study"],"prefix":"10.1177","volume":"59","author":[{"given":"Hayahide","family":"Ooi","sequence":"first","affiliation":[{"name":"Pharmacy, National Hospital Organization Mie Chuo Medical Center, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1933-8592","authenticated-orcid":false,"given":"Yuki","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kondo","sequence":"additional","affiliation":[{"name":"Pharmacy, National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Pharmacy, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Zakoji","sequence":"additional","affiliation":[{"name":"Pharmacy, National Hospital Organization Shizuoka Medical Center, Shimizu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aoki","sequence":"additional","affiliation":[{"name":"Pharmacy, National Center for Geriatrics and Gerontology, Obu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Koriyama","sequence":"additional","affiliation":[{"name":"Graduate School and Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mie University Hospital, Faculty of Medicine, Mie University, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Pharmacy, National Hospital Organization Mie Chuo Medical Center, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002808802200309"},{"key":"e_1_3_2_3_2","unstructured":"The Japanese Society of Chemotherapy The Japanese Association for Infectious Diseases. MRSA treatment guidelines 2024. Published 2024. Accessed January 17 2025. https:\/\/www.chemotherapy.or.jp\/modules\/guideline\/index.php?content_id=147#guideline-pdf"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-00424-3"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1679-45082011AO2020"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009x.2000.11782314"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S37528"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00544566"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13366"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.01.019"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.21-080"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b23-00469"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02290-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.01.024"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.03.007"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.06.003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241255837"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-58205-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024723"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2114"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1787062"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13866"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.12.2551"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039030-00001"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab499"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.019"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2020-002575"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03157-14"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.911393"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0253396"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-016-4121-6"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i13.1373"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-340"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/23.6.849"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2019.04.006"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251319519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251319519","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251319519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:01Z","timestamp":1777374841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251319519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/10600280251319519"],"URL":"https:\/\/doi.org\/10.1177\/10600280251319519","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]}}}